Skip to main content

Advertisement

Table 1 General characteristics at baseline and clinical findings during follow-up of the study population (n = 54)

From: Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study

Parameter  
Age (years), median [IQR] 60 [58–63]
Sex, no. (%)
 M/F 46 (85)/8 (15)
BMI, kg/m2, median [IQR] 27 [25.5–28.1]
Blood pressure (mmHg), median [IQR]
 Systolic 130 [120–131.2]
 Diastolic 80 [70–80]
Hypertension, no. (%) 15 (28)
Smoke, no. (%) 43 (80)
Cholesterol (mg/dL), median [IQR]
 Total 172 [149.5–189]
 HDL 42.5 [35–51]
 LDL 103 [68–128]
Triglycerides (mg/dL), median [IQR] 127 [105.2–151.5]
Glycemia (mg/dL), median [IQR]
 Baseline 87 [80–90.2]
 2 h 109 [93–126.7]
Glycated hemoglobin (%), median [IQR] 5.2 [5.1–5.5]
Insulin (µU/mL), median [IQR] 3.8 [3–6]
HOMA IR, median [IQR] 0.78 [0.59–1.31]
Creatinine (mg/dL), median [IQR] 1 [0.87–1.1]
Hemoglobin (mg/dL), median [IQR] 14.3 [13.3–15.2]
Adiponectin (µg/mL), median [IQR] 11 [9.7–13.2]
Adiponectin, no. (%)
 Pathologic 13 (24)
Resistin (ng/mL), median [IQR] 7 [4–9]
Resistin, no. (%)
 Pathologic 8 (15)
 TNF-alpha (ng/mL), median [IQR] 8.5 [7–11]
TNF-alpha, no. (%)
 Pathologic 6 (11)
Site of stenosis at first PCI, no. (%)
 IVA 25 (46)
 CX 10 (19)
 DX 19 (35)
Follow-up duration (months), median [IQR] 29.5 [14.7–34]
Re-PCI, no. (%) 4 (7)
Time re-PCI, median [IQR] 8.5 [4–15.75]
Site of re-PCI, no. (%)
 IVA 3 (75)
 CX 0 (−)
 DX 1 (25)
New PCI, no. (%) 5 (9)
Time new PCI, median [IQR] 29 [IQR 12–33.5]
Site of new-PCI, no. (%)
 IVA 2 (40)
 CX 1 (20)
 DX 2 (40)
Death, no. (%)
 Cardiovascular/other causes − /1 (2)